Memantine as a pain management strategy post-total knee arthroplasty: a randomized controlled trial
- 8 April 2026
- journal article
- research article
- Published by Springer Nature in European Journal of Orthopaedic Surgery & Traumatology
- Vol. 36 (1)
Abstract
Total knee arthroplasty (TKA) provides significant pain relief and improved function for patients with knee osteoarthritis. Despite its effectiveness, postoperative pain remains a major challenge. Effective management of this acute postoperative pain is critical for enhancing recovery. The study investigates the effectiveness of memantine in reducing postoperative pain in patients undergoing TKA. This double-blind, randomized controlled trial aimed to evaluate the efficacy of memantine for managing postoperative pain after TKA. Conducted from April to September 2022, eligible participants over 18 years with ASA grades I or II were recruited. Exclusions included patients with substance abuse histories, chronic opioid use, significant comorbidities, or contraindications to memantine. Participants were randomly assigned to receive either memantine (20 mg daily preoperatively for three days and 10 mg daily postoperatively for two weeks) or a placebo. Both groups received standard analgesics during hospitalization and upon discharge. Pain levels were assessed using Visual Analog Scale (VAS) scores and Short-Form McGill Pain Questionnaire (SF-MPQ) at various time points. Secondary outcomes measured included opioid usage and nocturnal awakening. Memantine did not significantly lower pain levels compared to placebo, as measured by VAS (mean difference: 0.138, CI 95%: - 0.468-1.103, P = 0.418) and SF-MPQ (mean difference: 1.962, CI 95%: - 1.013-4.936, P = 0.190). Patients receiving memantine needed opioid analgesia (2.85 ± 0.67 times) significantly (P < 0.001) less frequently than the Placebo patients (4.14 ± 1.06 times). Nocturnal awakening did not differ significantly between the two groups (Memantine: 3.59 ± 2.15, Placebo: 2.33 ± 2.12, P = 0.067). The comparison of pain levels between oral memantine and placebo indicates that memantine does not significantly reduce pain in patients undergoing TKA. However, it significantly lowers the need for opioids postoperatively.Keywords
This publication has 33 references indexed in Scilit:
- Memantine: updates from the past decade and implications for future novel therapeutic applicationsJournal of Neural Transmission, 2025
- Prevalence and risk factors for prolonged opioid use after total joint arthroplasty: a systematic review, meta-analysis, and meta-regressionArchives of orthopaedic and trauma surgery, 2020
- The Association Between Potential Opioid-Related Adverse Drug Events and Outcomes in Total Knee Arthroplasty: A Retrospective StudyAdvances in Therapy, 2019
- Expanding Role of NMDA Receptor Antagonists in the Management of PainCNS Drugs, 2019
- Additional benefit of local infiltration of analgesia to femoral nerve block in total knee arthroplasty: double-blind randomized control studyKnee Surgery, Sports Traumatology, Arthroscopy, 2018
- NMDA Receptors in the Central Nervous System2017
- Efeitos da memantina sobre a recuperação, funções cognitivas e dor após a anestesia com propofolRevista Brasileira de Anestesiologia, 2016
- Memantine improves buprenorphine/naloxone treatment for opioid dependent young adultsDrug and Alcohol Dependence, 2015
- Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s DiseaseClinical Pharmacokinetics, 2013
- Therapeutic brain concentration of the NMDA receptor antagonist amantadineNeuropharmacology, 1995